Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
08:00am, Friday, 14'th Feb 2025
LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference
Earnings Preview: Bausch Health (BHC) Q4 Earnings Expected to Decline
11:06am, Wednesday, 12'th Feb 2025
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
08:00am, Monday, 10'th Feb 2025
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology
Contact lens maker Bausch + Lomb rules out take-private deal
07:27am, Thursday, 06'th Feb 2025
Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday.
Bausch Health Provides Update on Strategic Alternatives
07:05am, Thursday, 06'th Feb 2025
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives throu
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
07:00am, Thursday, 23'rd Jan 2025
LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, Febr
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
07:00am, Wednesday, 22'nd Jan 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarte
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
09:25am, Friday, 17'th Jan 2025
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for
Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?
11:01am, Thursday, 16'th Jan 2025
The mean of analysts' price targets for Bausch (BHC) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i
Bausch + Lomb CEO on the negative impact of screen time on eye health
02:15pm, Tuesday, 14'th Jan 2025
Brent Saunders, Bausch and Lomb CEO, discusses how too much screen time can have a negative impact on vision.
Bausch and Lomb CEO: Right on track with our important initiatives
12:24pm, Tuesday, 14'th Jan 2025
Brent Saunders, Bausch and Lomb CEO, joins 'Money Movers' to discuss how Saunders has changed the portfolio in his time as chief executive, what the growth is like for Bausch and Lomb, and much more.
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
07:00am, Monday, 13'th Jan 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate h
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
06:00am, Monday, 13'th Jan 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial
